Efficacy and Safety of Concurrent Chemoradiotherapy Combined with Nimotuzumab in Elderly Patients with Esophageal Squamous Cell Carcinoma: A Prospective Real-world Pragmatic Study

被引:3
|
作者
Yu, Nuo [1 ]
Cheng, Guowei [2 ]
Li, Jiao [1 ]
Liang, Jun [1 ]
Zhang, Tao [1 ]
Deng, Lei [1 ]
Liu, Wenyang [1 ]
Wang, Jianyang [1 ]
Zhai, Yirui [1 ]
Wang, Wenqing [1 ]
Xiao, Zefen [1 ]
Zhou, Zongmei [1 ]
Chen, Dongfu [1 ]
Feng, Qinfu [1 ]
Bi, Nan [1 ]
Wang, Xin [1 ,3 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc,Dept Radiat Oncol, Beijing, Peoples R China
[2] Canc Hosp HuanXing, Dept Radiat Oncol, Beijing, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc,Dept Radiat Oncol, 17 Panjiayuan Nanli, Beijing 100021, Peoples R China
关键词
ESCC; nimotuzumab; elderly patients; chemoradiotherapy; overall survival; progression-free survival; RADIATION-THERAPY; PHASE-II; DEFINITIVE CHEMORADIOTHERAPY; CANCER; RADIOTHERAPY; CETUXIMAB; MULTICENTER; EXPRESSION; SURVIVAL;
D O I
10.2174/1568009623666230315145937
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Concurrent or definitive chemoradiotherapy is the standard treatment of locally advanced esophageal squamous cell carcinoma (ESCC). Elderly patients could not tolerate the standard concurrent chemotherapy and were treated with radiotherapy because of weak physical status and multiple comorbidities. Objective The efficacy and safety profile of concurrent (chemo) radiotherapy combined with nimotuzumab in elderly patients with ESCC were investigated. Methods Eligible elderly (& GE;70 years) patients with locally advanced ESCC were enrolled in this prospective, real-world pragmatic study and received concurrent chemoradiotherapy or radiotherapy combined with nimotuzumab. The primary endpoint was overall survival (OS). Secondary endpoints were objective response rate, disease control rate, progression-free survival (PFS), and adverse drug reactions. Results Fifty-three elderly patients were enrolled. Thirty-two (60.4%) were treated with radiotherapy combined with nimotuzumab (RT+N), and 21 (39.6%) with concurrent chemoradiotherapy combined with nimotuzumab (CRT+N). The median age was 75.8 years. Fourteen (56.0%) patients achieved a partial response, and 11 (44.0%) patients achieved stable disease at 3 months. The median follow-up duration was 24.4 (95%CI, 21.6-26.7) months. Median OS (mOS) was 27.0 (95%CI, 14.8-48.4) months. Median PFS (mPFS) was 22.6 (95%CI, 12.4-not reached) months. Higher mPFS (not reached vs. 12.0 months; p=0.022) and mOS (48.4 vs. 15.3 months; p=0.009) were observed in the CRT+N group compared with the RT+N group. Most adverse reactions were grade 1-2 (46, 86.8%). Conclusions Concurrent chemoradiotherapy or radiotherapy combined with nimotuzumab was safe and well-tolerated in elderly patients with locally advanced ESCC. ESCC patients treated with CRT+N could live longer.
引用
收藏
页码:653 / 662
页数:10
相关论文
共 50 条
  • [21] Efficacy and safety of high dose versus standard dose radiotherapy in concurrent chemoradiotherapy for patients with esophageal squamous cell carcinoma
    任雪姣
    China Medical Abstracts(Internal Medicine), 2019, 36 (03) : 165 - 166
  • [22] Efficacy and safety of the combination of tisleizumab with chemoradiotherapy in oligorecurrence esophageal squamous cell carcinoma: A prospective phase II study
    Zheng, Ziyu
    Wang, Xiaomin
    Liu, Xinqiang
    Zhao, Yidian
    Yu, Nuo
    Li, Jiao
    Feng, Guojie
    Qin, Jianjun
    Kang, Xiaozheng
    Li, Yong
    Wang, Zhen
    Chen, Xiankai
    Zhang, Ruixiang
    Zheng, Qingfeng
    Bi, Nan
    Li, Yin
    Wang, Xin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] Efficacy and Safety of the Combination of Tislelizumab with Chemoradiotherapy in Oligorecurrence Esophageal Squamous Cell Carcinoma: A Prospective Phase II Study
    Zheng, Z.
    Wang, X. M.
    Liu, X.
    Zhao, Y. D.
    Yu, N.
    Feng, G.
    Qin, J.
    Kang, X.
    Li, Y.
    Wang, Z.
    Chen, X.
    Zhang, R.
    Zheng, Q.
    Bi, N.
    Li, Y.
    Wang, X.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E508 - E509
  • [24] A Novel Predictive Model of Efficacy for Concurrent Chemoradiotherapy in Esophageal Squamous Cell Carcinoma
    Yang, X.
    Liu, J.
    Feng, B.
    Luo, H.
    Chen, L.
    Tan, L.
    Jin, F.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E202 - E202
  • [25] Nimotuzumab Combined With Concurrent Chemoradiation Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
    Zhai, Y. R.
    Hui, Z.
    Wang, X.
    Liang, J.
    Wang, W.
    Feng, Q.
    Zhou, Z.
    Wang, X.
    Xiao, Z.
    Bi, N.
    Wang, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E205 - E205
  • [26] Slight advantages of nimotuzumab versus cetuximab plus concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma
    Jing, Wang
    Yan, Weiwei
    Liu, Yuguo
    Li, Ji
    Yu, Jinming
    Zhu, Hui
    CANCER BIOLOGY & THERAPY, 2019, 20 (08) : 1121 - 1126
  • [27] Definitive concurrent chemoradiotherapy with S-1 and cisplatin in elderly esophageal squamous cell carcinoma patients
    Wang, Hongqing
    Li, Gang
    Chen, Lifang
    Duan, Yuxia
    Zou, Chunpeng
    Hu, Chunhong
    JOURNAL OF THORACIC DISEASE, 2017, 9 (03) : 646 - 654
  • [28] Real-world clinical effectiveness and safety of camrelizumab in esophageal squamous cell carcinoma.
    Yao, Qiwei
    Fu, Zhichao
    Chen, Qisong
    Huang, Jianli
    Wu, Jintong
    Ke, Chunlin
    Ma, Liangyun
    Li, Shouguo
    He, Rongqi
    Lin, Yuyi
    Li, Jiancheng
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] Efficacy and safety of nimotuzumab plus radiotherapy for elderly patients with locally advanced cervical squamous cell carcinoma
    Qu, A.
    Wang, J.
    Zhuo, Y.
    Liu, Z.
    Zhu, H.
    Wei, L.
    Sun, X.
    Gao, Y.
    Cheng, H.
    Zhao, F.
    Song, Y.
    Wen, Q. L.
    Zhou, X.
    Wang, P.
    Yang, J.
    Zou, L.
    Yuan, X.
    Wu, D.
    He, J.
    Zhang, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S519 - S519
  • [30] Real-world outcomes of surgery versus chemoradiotherapy for clinical stage I esophageal squamous cell carcinoma
    Sawada, Kentaro
    Fujiwara, Hisashi
    Yukami, Hiroki
    Mishima, Saori
    Kotani, Daisuke
    Kadota, Tomohiro
    Inaba, Atsushi
    Nishihara, Keiichiro
    Sato, Daiki
    Nakajo, Keiichiro
    Yoda, Yusuke
    Nakamura, Masaki
    Hojo, Hidehiro
    Yano, Tomonori
    Fujita, Takeo
    Kojima, Takashi
    ANNALS OF ONCOLOGY, 2021, 32 : S310 - S310